Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Editas Medicine (EDIT) over the last 10 years, with Q3 2025 value amounting to $183.6 million.

  • Editas Medicine's Total Non-Current Liabilities rose 2351.67% to $183.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $183.6 million, marking a year-over-year increase of 2351.67%. This contributed to the annual value of $204.2 million for FY2024, which is 3776.37% up from last year.
  • Editas Medicine's Total Non-Current Liabilities amounted to $183.6 million in Q3 2025, which was up 2351.67% from $186.8 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Total Non-Current Liabilities ranged from a high of $204.2 million in Q4 2024 and a low of $142.5 million during Q1 2024
  • Its 4-year average for Total Non-Current Liabilities is $168.0 million, with a median of $153.6 million in 2022.
  • As far as peak fluctuations go, Editas Medicine's Total Non-Current Liabilities tumbled by 350.49% in 2023, and later skyrocketed by 3776.37% in 2024.
  • Quarter analysis of 4 years shows Editas Medicine's Total Non-Current Liabilities stood at $153.6 million in 2022, then decreased by 3.5% to $148.3 million in 2023, then soared by 37.76% to $204.2 million in 2024, then decreased by 10.1% to $183.6 million in 2025.
  • Its last three reported values are $183.6 million in Q3 2025, $186.8 million for Q2 2025, and $194.9 million during Q1 2025.